UNSPSC 51372000: Controlled substance analgesic morphinans

Controlled substance analgesic drugs made from compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes.

UNSPSC 51372000 Controlled substance analgesic morphinans is a Class code covering pharmaceutical products and related systems that state and local governments procure to support public health, emergency response, and community health initiatives. Recent opportunities show state and local buyers acquiring naloxone (a controlled-substance antagonist), generic multi-source pharmaceuticals, and drug deactivation systems through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances, with work ranging from direct product procurement to market-intelligence gathering on pharmacy benefit programs.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, assessing potential for direct contracting between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract award effective July 1, 2026; vendors must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, and pricing is weighted 75 percent on competitiveness.